article thumbnail

HP&M Director, Allyson Mullen, Appointed to the Association of Medical Diagnostic Manufacturers 2024-2026 Board of Directors

FDA Law Blog: Biosimilars

Hyman, Phelps & McNamara, P.C. (HP&M), HP&M), the largest dedicated food and drug law firm in the U.S., is pleased to announce that Director Allyson Mullen has been appointed to the Board of Directors of the Association of Medical Diagnostic Manufacturers (AMDM). This prestigious appointment recognizes Ms.

article thumbnail

AZ to invest $400 million in reforestation and biodiversity

Drug Discovery World

The company is on track to reduce greenhouse gas emissions (GHGs) from its operations and fleet by 98% by 2026 and halve its value chain footprint by 2030. It hopes to achieve a 90% absolute emissions reduction and becoming science-based net zero by 2045 at the latest.

Science 246
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

GSK partners with Chinese pharma to expand Shingrix sales

BioPharma Drive: Drug Pricing

The purchase agreement with Chongqing Zhifei Biological Products is part of GSK’s plan to double sales of the shingles vaccine by 2026.

Vaccine 110
article thumbnail

$225m to advance novel immune checkpoint enhancer programme

Drug Discovery World

This study is anticipated to read out in 2H of 2026. The company plans to initiate a global Phase IIb randomised, placebo-controlled clinical trial with a primary endpoint of clinical remission in both advanced therapy experienced and treatment naive patients with moderately to severely active UC.

article thumbnail

Study finds dual receptor beta-agonist promotes healthy weight loss

Drug Discovery World

We are now advancing our next generation small molecules for the treatment of obesity to IND preparatory studies in H1 next year and expect to enter the clinic in 2026.” Atrogi is also conducting trials into ATR-258, a novel b2adrenoceptor agonist for the treatment of type 2 diabetes and comorbidities.

article thumbnail

Changes to UK Statutory Scheme go ahead despite pharma criticism

Drug Discovery World

It intends to set amended payment percentages for 2024 to 2026 based on an allowed growth rate that has been increased to 2%. This means that companies will pay a rebate on the sales of branded medicines to the NHS of 21.9% in 2024, 24% in 2025 and 26.8%

article thumbnail

Bluebird, short on cash, takes on $175M in debt financing

BioPharma Drive: Drug Pricing

The funding could extend the cash-strapped gene therapy maker’s financial runway to 2026, but only if the company successfully hits certain milestones.